Organization
Shanghai Jiatan Pharmatech
8 clinical trials
Clinical trial
A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase II Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 MutationsStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase Ⅰ Study of PI3K/mTOR Dual Inhibitor WXFL10030390 to Evaluate the Safety, Tolerability and Pharmacokinetics in Patients With Advanced Solid Tumors or LymphomaStatus: Completed, Estimated PCD: 2020-07-25
Clinical trial
A Multi-center, Randomized, Positive-controlled Phase 2 Clinical Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of WX-081 in Participants With Drug-naive&Susceptible or Drug-Resistant Pulmonary TuberculosisStatus: Completed, Estimated PCD: 2022-04-13
Clinical trial
A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-ascending Phase I Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of Sudapyridine (WX-081) Tablets in Healthy Chinese SubjectsStatus: Completed, Estimated PCD: 2020-07-02
Clinical trial
A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390, a PI3K/mTOR Dual Inhibitor, for the Treatment of Advanced Solid Tumors With PIK3CA MutationsStatus: Completed, Estimated PCD: 2023-01-03
Clinical trial
A Multicenter, Randomized, Double-blind, Positive Control Study to Evaluate the Efficacy and Safety of Sudapyridine (WX-081) Tables in Patients With Rifampicin-resistant Pulmonary TuberculosisStatus: , Estimated PCD: 2025-01-22
Clinical trial
An Open-label, Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of WX390 in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-01